Brugada Syndrome 7 (BrS7): A Comprehensive Disease Characterization Report

Disease: Brugada syndrome 7 · Gene: SCN3B (Navβ3) · OMIM: #613120 · Category: Genetic (cardiac channelopathy) Evidence status: SCN3B has "limited" gene–disease validity for Brugada syndrome (SCN5A is the sole "definitive" gene)

Autonomous literature-based investigation. Evidence types are flagged as [human clinical], [in vitro], [model organism], [computational], or [database]. Where primary data specific to the SCN3B/BrS7 subtype are lacking, general Brugada-syndrome (BrS) evidence is used and labeled as such.

Summary

Brugada syndrome 7 (BrS7; OMIM #613120) is a rare, autosomal-dominant cardiac sodium channelopathy attributed to loss-of-function variants in SCN3B, the gene encoding the auxiliary β3 subunit (Navβ3) of the cardiac voltage-gated sodium channel. Mutant β3 fails to properly chaperone and modulate the pore-forming Nav1.5 (SCN5A) α-subunit, reducing its cell-surface expression and cardiac sodium current (I_Na) [in vitro, PMID 23257389]. The reduced inward sodium current unmasks transient-outward-current (I_to)-mediated repolarization heterogeneity in the right ventricular outflow tract (RVOT), which generates the diagnostic type-1 (coved) Brugada ECG pattern and creates a phase-2-reentry substrate for polymorphic ventricular tachycardia (VT), ventricular fibrillation (VF), and sudden cardiac death (SCD) [in vitro, PMID 24657694].

Clinically, BrS7 is indistinguishable from other Brugada subtypes. It presents predominantly in adult males (~95% male, mean age ~51 years), is unmasked or triggered by fever, sodium-channel-blocking drugs, enhanced vagal tone, and electrolyte imbalance, and is managed with implantable cardioverter-defibrillators (ICDs), quinidine, isoproterenol/adrenaline for electrical storms, epicardial RVOT substrate ablation, and trigger avoidance. There is no gene-specific therapy for the SCN3B subtype.

A critical caveat governs the entire entity: evidence-based gene-curation (ClinGen-style reappraisal by Hosseini et al., 2018) classified SCN3B as having only "limited" clinical validity for Brugada syndrome, with SCN5A being the only gene reaching "definitive" evidence [PMID 29959160]. Contemporary expert consensus reinforces that SCN5A "remains the sole gene with definitive disease association" and that BrS displays complex, oligogenic/polygenic inheritance [PMID 41738055]. BrS7 is therefore best regarded as a rare, disputed monogenic subtype nested within a broader genetic architecture. This report is compiled from aggregated disease-level resources (OMIM, HGNC, UniProt) and primary literature (human clinical cohorts, in-vitro electrophysiology, and a Scn3b-knockout mouse), not individual EHR data.

Key Findings

Finding 1 — BrS7 is caused by loss-of-function SCN3B variants that reduce cardiac sodium current via impaired Nav1.5 trafficking

BrS7 (OMIM #613120) is caused by heterozygous mutations in SCN3B, encoding the auxiliary β3 subunit (Navβ3) of the cardiac sodium channel. In the seminal functional study of the Japanese SCN3B-V110I variant, transfected cells showed decreased Nav1.5 cell-surface expression and significantly reduced sodium current — a clear loss-of-function effect. As the authors reported, "The SCN3B mutation impaired the cytoplasmic trafficking of Nav1.5, the cell surface expression of which was decreased in transfected cells," and "Whole-cell patch clamp recordings of the transfected cells revealed that the sodium currents were significantly reduced by the SCN3B mutation" [in vitro, PMID 23257389]. A newly characterized in-frame deletion (p.T138del, 2025) confirms ongoing identification of BrS-associated SCN3B variants; the paper "identify and characterise a novel SCN3B variant encoding the regulatory β3-subunit of the cardiac voltage-gated sodium channel" [human/in vitro, PMID 39761910]. This establishes the core molecular lesion: reduced I_Na from a defective auxiliary subunit.

Finding 2 — SCN3B is a rare cause of SCN5A-negative Brugada syndrome (~1.7% in a Japanese cohort)

Among 181 unrelated SCN5A-negative BrS patients (178 Japanese, 3 Korean), the SCN3B Val110Ile variant was found in only 3 of 178 (1.7%) Japanese patients and was absent from 480 Japanese controls: "A mutation, Val110Ile, was identified in 3 of 178 (1.7%) Japanese patients, but was not found in 480 Japanese controls" [human, PMID 23257389]. Set against the broader diagnostic landscape — "A pathogenic/likely pathogenic variant can be found in 20% to 25% of patients with Brugada syndrome (BrS) and a pathogenic/likely pathogenic variant in SCN5A is associated with a worse prognosis" [human clinical, PMID 38426305] — SCN3B accounts for a small fraction of the minor BrS genes.

Finding 3 — The Scn3b-knockout mouse recapitulates conduction slowing and atrial arrhythmia susceptibility

Scn3b(−/−) mice showed slower heart rates, longer P-wave durations, and prolonged PR intervals versus wild-type, plus abnormal atrial electrophysiology and inducible atrial tachycardia/fibrillation on burst pacing. As reported, "Lead I electrocardiograms from Scn3b(-/-) mice showed slower heart rates, longer P wave durations and prolonged PR intervals than WT hearts," and "Atrial burst pacing protocols induced atrial tachycardia and fibrillation in all Scn3b(-/-) but hardly any WT hearts" [model organism, PMID 19796257]. Because Scn1b and Scn5a mRNA were unchanged, the phenotype is attributable specifically to β3 loss.

Finding 4 — The BrS arrhythmia substrate arises from RVOT epicardial repolarization heterogeneity and concealed phase-2 reentry

In coronary-perfused canine RV wedge preparations pharmacologically mimicking the BrS genotype (I_to-agonist NS5806 + Ca-channel blocker verapamil), "Fractionated electrical activity was observed in RV epicardium, but not in endocardium, as a consequence of heterogeneities in the appearance of the second upstroke of the epicardial action potential, and discrete high-frequency spikes developed as a result of concealed phase 2 re-entry" [in vitro, PMID 24657694]. Contemporary consensus reframes BrS as a microstructural–electrical continuum: "BrS, once viewed as a purely electrical disorder, is now recognized along a microstructural-electrical continuum, with sodium-channel dysfunction and subtle epicardial fibrosis of the right ventricular outflow tract as key contributors" [human clinical, PMID 41738055].

Finding 5 — Fever, sodium-channel-blocking drugs, vagal tone, and electrolyte imbalance unmask the type-1 pattern and trigger arrhythmias

Fever is a well-established trigger that unmasks the coved type-1 ECG and precipitates VF, including as a first manifestation across ages. Reviews list precipitating factors succinctly: "Brugada syndrome could be precipitated by various factors, such as fever, electrolyte imbalances, and drugs" [human clinical, PMID 42411811], and "Fever is a well-known trigger for malignant ventricular arrhythmias in predisposed patients" [human clinical, PMID 42200267]. This is the paradigmatic gene–environment interaction of the disease.

Finding 6 — Management centers on ICD and quinidine, with epicardial RVOT substrate ablation as an emerging therapy

"For decades, treatment centered on implantable cardioverter-defibrillators and quinidine, both limited by availability, tolerance, and device complications. More recently, epicardial substrate ablation has emerged as a transformative therapy" [human clinical, PMID 41738055]. Quinidine efficacy is quantified in an Israeli survey with "inducible ventricular fibrillation (VF) in 10, which was prevented by quinidine in 9/10 patients" [human clinical, PMID 29761670]. There is no gene-specific therapy for SCN3B-related BrS7.

Finding 7 — BrS is strongly male-predominant with mid-adult presentation; SCN5A is the only definitively validated gene

Large Japanese prospective registries report cohorts of ~95% men with mean age ~51 years: "We analyzed 510 patients with BrS (mean age 51 ± 14 years; 95% men)" [human clinical, PMID 41819241]. Expert consensus states "SCN5A remains the sole gene with definitive disease association, while polygenic susceptibility materially modulates risk, underscoring complex inheritance" [human clinical, PMID 41738055] — implying minor genes including SCN3B have limited monogenic validity.

Finding 8 — SCN3B has only LIMITED clinical validity as a Brugada syndrome gene

In the evidence-based reappraisal of BrS genes (ClinGen-style semiquantitative scoring, three independent curation teams + clinical domain expert panel), "Of 21 genes curated for clinical validity, biocurators classified only 1 gene (SCN5A) as definitive evidence, whereas all other genes were classified as limited evidence" [computational/curation, PMID 29959160]. SCN3B (the basis of the BrS7/#613120 designation) falls among the limited-evidence genes.

Finding 9 — SCN3B loss-of-function variants also cause early-onset lone atrial fibrillation (an allelic phenotype)

Olesen et al. sequenced SCN3B in 192 unrelated lone AF patients and found three non-synonymous mutations (R6K, L10P, M161T), absent from 432 control alleles, all affecting conserved residues: "The three mutations in SCN3B were investigated electrophysiologically and all led to loss of function in the sodium current, supporting the hypothesis that decreased sodium current enhances AF suscepti[bility]" [in vitro/human, PMID 21051419]. Separately, GATA4-regulated 5′UTR/promoter SCN3B variants were linked to lone AF via a gain-of-function increase in expression [in vitro, PMID 36362949], illustrating context-dependent directionality.

Finding 10 — Diagnosis rests on the type-1 ECG (spontaneous or drug-provoked) and the Shanghai score

Diagnosis requires a coved-type (type-1) ST-elevation ECG in leads V1–V2, spontaneous or unmasked by sodium-channel-blocker provocation (ajmaline/flecainide). A large drug-provocation study "involved 698 patients with drug-induced type 1 BrS, confirmed via pharmacologic challenge (flecainide or ajmaline), from 21 centers in Italy and Switzerland" [human clinical, PMID 40996547]. In that cohort, "SCN5A pathogenic variants were a significant predictor of primary endpoint in the possible BrS group (OR: 12.5)" — showing SCN5A, not minor genes like SCN3B, drives prognostic weight.

Finding 11 — SCN3B encodes Navβ3, a single-pass glycoprotein with an extracellular Ig domain that chaperones and modulates Nav1.5

SCN3B (HGNC:10592; gene OMIM 608214; 11q24.1; UniProt Q9NY72) encodes an auxiliary single-transmembrane protein with an extracellular immunoglobulin (Ig)-like fold and short intracellular tail. It associates non-covalently with Nav1.5, modulating gating and promoting surface trafficking. Reports confirm "the VGSC β3 subunit (the product of SCN3B gene)... its extracellular immunoglobulin domain (β3 Ig)" [in vitro, PMID 40245999] and that "a mutation in SCN3B for a small subunit of sodium channel, Navβ3, has been recently reported" [in vitro, PMID 23257389].

Section-by-Section Characterization

1. Disease Information

BrS7 is a genetic subtype of Brugada syndrome — a primary inherited arrhythmia syndrome characterized by ST-segment elevation in the right precordial ECG leads (V1–V2) and increased SCD risk in a structurally near-normal heart.

Synonyms: Brugada syndrome type 7; BRGDA7; SCN3B-related Brugada syndrome. Historical/allelic clinical descriptors: sudden unexplained nocturnal death syndrome (SUNDS), "Lai Tai," "Bangungut" [human clinical, PMID 24529773]. Data provenance: aggregated disease-level resources plus individual case reports and small functional studies (subtype-specific evidence is sparse).

2. Etiology

Primary cause (genetic): heterozygous variants in SCN3B (Navβ3) [PMID 23257389; 39761910]. Genetic risk factors: V110I (recurrent in Japan), L10P, T138del, A195T (VUS); polygenic background near SCN5A-SCN10A and HEY2 modulates risk [PMID 41738055; 41458990]. Environmental triggers (unmask rather than cause): fever (most important), sodium-channel-blocking drugs, propofol/local anaesthetics, enhanced vagal tone, electrolyte abnormalities, alcohol, cocaine, and male sex [PMID 42411811; 42200267; 41819241]. Protective factors: no validated protective allele; trigger avoidance (aggressive fever control, avoiding contraindicated drugs) is the principal modifiable protection; female sex/older age associate with lower event rates [PMID 40130219]. Gene–environment interaction: the temperature-sensitive mutant channel loses further function during fever, deepening the epicardial repolarization gradient [PMID 42200267].

3. Phenotypes

Onset: predominantly adult (3rd–5th decade); pediatric and elderly first presentations occur. Severity/progression: highly variable and episodic; most carriers asymptomatic; risk lifelong. QoL impact: anxiety about SCD, activity/occupational restrictions, ICD-related psychological burden and inappropriate shocks (ICD complications ~20% in a pediatric cohort) [PMID 31748893]. No disease-specific QoL instrument; generic EQ-5D/SF-36 apply.

4. Genetic / Molecular Information

Causal gene: SCN3B (Navβ3). Reported variants (germline, heterozygous):

ACMG classification: most variants VUS/limited-evidence given disputed gene validity [PMID 29959160]. Allele frequency: rare/absent in controls (check gnomAD per variant). Functional consequence: predominantly loss of function; regulatory gain-of-function branch for AF [PMID 36362949]. Modifier genes: SCN5A genotype + polygenic background [PMID 41738055]. Epigenetics: GATA4 transcriptionally regulates SCN3B [PMID 36362949]; no disease-specific methylation signature or characteristic chromosomal abnormality.

5. Environmental Information

Sodium-channel-blocking drugs, anaesthetics (propofol, bupivacaine), cocaine, and certain tyrosine-kinase inhibitors can unmask the pattern (a Brugada phenocopy was reported with avapritinib during febrile illness) [PMID 42165456; 42411811]. Large meals, alcohol, and dehydration/electrolyte shifts provoke events. Infectious agents: none causative; febrile infections (any cause, e.g., influenza) are a major arrhythmic trigger by unmasking the type-1 pattern [PMID 42647943].

6. Mechanism / Pathophysiology

Ordered causal chain (mutation → clinical manifestation):

1. A heterozygous SCN3B (Navβ3) variant alters the auxiliary β3 subunit [DEMONSTRATED in vitro, PMID 23257389]. →
2. Mutant β3 fails to chaperone/modulate Nav1.5, leading to reduced Nav1.5 surface expression [DEMONSTRATED, PMID 23257389; 39761910]. →
3. This results in reduced peak cardiac sodium current (I_Na) — a loss-of-function channelopathy [DEMONSTRATED by patch clamp, PMID 23257389]. →
4. Reduced I_Na allows the I_to-mediated phase-1 notch to dominate the epicardial action potential, most prominently in RVOT epicardium (highest I_to), leading to loss of the AP dome at some sites [INFERRED from wedge models, PMID 24657694]. →
5. Heterogeneous dome loss creates transmural/epicardial dispersion of repolarization, producing the coved type-1 ST elevation and concealed phase-2 reentry [PMID 24657694]. →
6. Phase-2 reentry triggers closely coupled premature beats initiating polymorphic VT/VF [PMID 24657694]. →
7. VF results in syncope, aborted arrest, or SCD [PMID 41738055].
8. Modulating branch: fever / Na-blockers further reduce I_Na at step 3 [PMID 42200267].
9. Structural branch: subtle RVOT epicardial fibrosis contributes (microstructural–electrical continuum) [PMID 41738055].
10. Atrial branch: the same reduced-I_Na lesion promotes AF and conduction slowing [PMID 21051419; 19796257].

Supporting detail. Molecular pathway/biochemical defect: cardiac Nav (Nav1.5 + β subunits) dysfunction — an ion-channel defect, not metabolic/enzymatic. Suggested GO: GO:0005248 (voltage-gated sodium channel activity), GO:0086010 (membrane depolarization during action potential), GO:0001518 (voltage-gated sodium channel complex), GO:0086067 (bundle of His cell–Purkinje conduction), GO:0086091 (regulation of heart rate by cardiac conduction). Protein dysfunction: loss-of-function via impaired trafficking and altered gating; β3 uses its extracellular Ig domain for α-subunit interaction [PMID 40245999]. Cell types (CL): ventricular cardiomyocyte (CL:0002131), RVOT epicardial myocytes, Purkinje/conduction cells (CL:0000731/CL:0002068), SA-node cells (CL:1000488). Immune/metabolic: not primary. Omics: no established disease-specific transcriptomic/proteomic/metabolomic signature for BrS7.

7. Anatomical Structures Affected

• Organ: heart (UBERON:0000948); system: cardiovascular (UBERON:0004535).
• Primary site: RVOT / RV epicardium (UBERON:0004125; UBERON:0002082) — locus of the arrhythmic substrate [PMID 24657694]. Secondary: atria (UBERON:0002081) and conduction system (UBERON:0004146) — AF and conduction slowing.
• Secondary organ: brain (hypoxic-ischaemic injury from arrest) — a complication.
• Tissue/cell: cardiac muscle tissue (working ventricular/atrial + conduction myocytes); limited epicardial fibrosis (connective).
• Subcellular (GO CC): plasma membrane/sarcolemma, intercalated disc (GO:0014704), voltage-gated sodium channel complex (GO:0001518), endoplasmic reticulum (trafficking, GO:0005783).
• Lateralization: predominantly right-sided (RVOT); biventricular substrate can occur [PMID 42359113].

8. Temporal Development

Congenital genetic defect but clinically adult-onset (mean event age ~40 yr; late presentation to the 8th decade under febrile stress) [PMID 42200267]. Arrhythmia onset is acute/episodic (often at rest/sleep). The ECG substrate is chronic/lifelong; arrhythmic risk is episodic, not progressive; no defined "stages." Event incidence ~1.5%/yr (non-elderly) vs ~0.7%/yr (elderly) [PMID 40130219]. Critical vulnerable windows: febrile illness and administration of contraindicated drugs.

9. Inheritance and Population

Epidemiology (BrS overall): prevalence ~1 in 2,000–5,000, higher in Southeast/East Asia; BrS7/SCN3B is very rare (isolated families/probands). Inheritance: autosomal dominant with incomplete, age-dependent penetrance and variable expressivity [PMID 41458990]. Founder effects/consanguinity: none established; V110I recurs in Japan without a defined founder haplotype. Carrier frequency: not defined; individual variants rare in gnomAD. Demographics: strong male predominance (~8–9:1; ~95% men), attributed to testosterone-dependent I_to; mean age ~51 yr [PMID 41819241; 40130219]; geographic skew toward Asian populations.

10. Diagnostics

Cornerstone: spontaneous or drug-provoked type-1 coved ST-elevation ≥2 mm in ≥1 right precordial lead (V1–V2), including high lead placement [PMID 41738055]. Provocation with ajmaline/flecainide unmasks concealed cases (ajmaline positive in 76% of a suspected pediatric cohort) [PMID 42669184; 40996547]. Shanghai Score System integrates ECG, symptoms, family history, and genetics (≥3.5 = probable/definite) [PMID 40996547]; multiparametric models (Sieira, Brugada-Risk, PAT) [PMID 40314213]. Genetic testing: multigene NGS panel/WES including SCN5A, SCN1B–4B (incl. SCN3B), etc.; SCN5A highest-yield/most actionable, SCN3B findings usually VUS; overall P/LP yield ~20–25% [PMID 38426305]; cascade familial testing recommended [PMID 26230511]. Imaging: echo/CMR to exclude structural disease (ARVC, scar) [PMID 42359113]. Biomarkers/omics: none established. Differential diagnosis: Brugada phenocopies (fever, hyperkalaemia, ischemia, drugs), ARVC, early repolarization syndrome, RVOT-VT, athlete's ECG, atypical RBBB [PMID 42359113; 25548613]. Screening: no newborn/population screening; cascade ECG + genetic screening of first-degree relatives.

11. Outcome / Prognosis

Principal risk is SCD from VF; annual major-arrhythmic-event rate ~1.5%/yr (non-elderly) vs ~0.7%/yr (elderly), ~11% over long follow-up [PMID 40130219; 41819241]. Higher-risk factors: prior aborted arrest/VF, arrhythmic syncope, spontaneous (vs drug-induced) type-1 ECG, notched P wave/atrial conduction delay, SCN5A pathogenic variant; asymptomatic patients are lower-risk [PMID 41819241; 40996547]. SCN3B genotype is not an established independent prognostic marker. Morbidity: VF-related anoxic injury, ICD complications (inappropriate shocks, lead failure ~20% pediatric), electrical storms, AF [PMID 31748893]. Life expectancy: near-normal if high-risk individuals are protected (ICD) and triggers avoided; chronic/lifelong without cure.

12. Treatment

Genotype-agnostic; no SCN3B-specific therapy.

Evidence: quinidine prevented inducible VF in 9/10 [PMID 29761670]; epicardial ablation is transformative for high-risk/recurrent patients [PMID 41738055; 40088219]; isoproterenol/adrenaline rescue for electrical storms [PMID 40800556]. No approved gene/cell/RNA therapy; gene therapy/precision ablation are aspirational goals [PMID 40505939]. Personalized medicine is by risk score/phenotype, not SCN3B genotype.

13. Prevention

Primary: trigger avoidance (fever→antipyretics, avoid BrS-contraindicated drugs, moderate alcohol) [PMID 42411811]; no relevant immunization. Secondary: cascade ECG + genetic screening of first-degree relatives; risk stratification (Shanghai/Sieira) to select ICD candidates [PMID 40996547; 40314213]. Tertiary: ICD, quinidine, epicardial ablation [PMID 40088219]. Genetic counseling: AD 50% transmission risk; preimplantation genetic testing available for inherited cardiac disease, though limited-validity genes like SCN3B complicate variant-based PGT [PMID 38516780]. Public health: region-dependent pre-participation ECG screening and sports-eligibility guidance [PMID 40116545].

14. Other Species / Natural Disease

SCN3B orthologs: mouse Scn3b (NCBI Gene 235281; MGI), rat Scn3b (RGD), and orthologs in most vertebrates; β3's I_Na-modulatory function is evolutionarily conserved [PMID 19796257]. No naturally occurring SCN3B "Brugada" disease is catalogued in OMIA for companion animals/livestock; inherited ventricular arrhythmia/SCD syndromes exist in dogs (e.g., German Shepherd inherited ventricular arrhythmia) but are not SCN3B-defined. The reduced-I_Na → conduction/arrhythmia mechanism is conserved and validated in mouse. Zoonotic/transmission concepts are not applicable (non-infectious genetic disease).

15. Model Organisms

Mouse — Scn3b-knockout [PMID 19796257]: constitutive KO showing slower heart rate, longer P-wave, prolonged PR interval, abnormal sinoatrial/atrial electrophysiology, prolonged sinus-node recovery, and inducible atrial tachycardia/fibrillation (in essentially all KO vs almost no WT); Scn1b/Scn5a mRNA unchanged, isolating the β3 effect. Limitations: emphasizes atrial/conduction phenotypes; the human ventricular RVOT phase-2-reentry VF and spontaneous type-1 ECG are not straightforwardly reproduced (species differences in I_to distribution). Applications: SA-node function, atrial conduction, AF susceptibility.

In-vitro/cellular: heterologous expression (HEK-293/CHO) co-expressing Nav1.5 + mutant β3 for patch-clamp I_Na and trafficking/biotinylation assays [PMID 23257389; 39761910]; β-subunit-eliminated human haploid (BeHAPe) cells to study subunit regulation [PMID 37544648]. Patient-derived iPSC-cardiomyocytes are used broadly for BrS but no SCN3B-specific iPSC model was identified. Resources: MGI (Scn3b), IMPC, RGD.

Mechanistic Model / Interpretation

 SCN3B loss-of-function variant (V110I / L10P / T138del)
 │  alters Navβ3 auxiliary subunit
 ▼
 Impaired β3 chaperone/modulatory function          [DEMONSTRATED in HEK293]
 ▼
 ↓ Nav1.5 (SCN5A) trafficking → ↓ cell-surface channels   [DEMONSTRATED]
 ▼
 ↓ Peak cardiac sodium current (I_Na)  ◄── fever / Na-blocker drugs / vagal tone (TRIGGERS)
 │  [INFERRED for RVOT ventricle from canine wedge models]
 ▼
 I_to dominance in RV epicardium → loss of AP dome (accentuated notch)
 │
 ├──► Transmural + epicardial repolarization heterogeneity
 │            └► Type-1 coved ST elevation (V1–V2)  ── DIAGNOSIS
 │
 └──► Concealed PHASE-2 REENTRY (extrasystoles)
                   │
                   ▼
    Polymorphic VT / VF  ──►  Syncope / SCD
                   ▲
       (+ subtle epicardial RVOT fibrosis: microstructural–electrical continuum)

 Atrial branch: same ↓I_Na lesion → conduction slowing + inducible AF  [KO mouse; human AF variants]

Upstream vs downstream: the mutation and I_Na reduction are upstream; the I_to/repolarization imbalance, phase-2 reentry, and VF are downstream. Fever and drugs amplify anywhere along the I_Na axis. The unifying principle is a reduced-inward-current → repolarization-gradient → reentry cascade localized to the RVOT epicardium — the same final common pathway as SCN5A-related BrS, which is why BrS7 is clinically indistinguishable.

Evidence Base

Supported vs Refuted Hypotheses

Supported: - SCN3B loss-of-function reduces I_Na via impaired Nav1.5 trafficking → BrS ECG [PMID 23257389]. - The BrS substrate is RVOT epicardial repolarization heterogeneity with phase-2 reentry [PMID 24657694]. - Scn3b loss causes conduction slowing/atrial arrhythmia in vivo [PMID 19796257]. - SCN3B is also an allelic cause/susceptibility gene for atrial fibrillation [PMID 21051419].

Refuted / down-weighted: - The premise that SCN3B is a robustly validated monogenic BrS gene is not supported; evidence-based curation rates it "limited," with SCN5A the only definitive gene [PMID 29959160; 41738055].

Limitations and Knowledge Gaps

1. Disputed gene validity — SCN3B has only "limited" clinical validity; the BrS7 designation rests on few families/variants, and some historical assignments may be reclassified.
2. Sparse subtype-specific data — penetrance, prevalence, sex ratio, and prognosis are extrapolated from general BrS cohorts; no large SCN3B-specific natural-history study exists.
3. Model–human gap — the Scn3b-KO mouse reproduces atrial/conduction phenotypes but not the human RVOT ventricular VF substrate; canine wedge models are pharmacological, not SCN3B-genotype-specific.
4. Mechanistic gaps — the T138del variant showed normal surface expression, implying additional (gating/microdomain) mechanisms beyond trafficking [PMID 39761910].
5. No genotype-specific therapy or biomarker — management is generic BrS care; risk models carry high bias.
6. Directionality complexity — SCN3B shows loss-of-function (BrS, AF) and gain-of-function (promoter, AF) in different contexts, complicating variant interpretation.

Proposed Follow-up Experiments / Actions

1. Patient-derived iPSC-cardiomyocytes carrying SCN3B variants (± isogenic correction) with I_Na/I_to phenotyping and optical mapping in engineered RVOT-like tissue — to test the human ventricular substrate directly.
2. Formal ClinGen re-curation of SCN3B incorporating post-2018 variants (e.g., T138del), segregation, and functional data to update gene-validity classification.
3. Population-scale variant assessment in gnomAD/TOPMed to establish allele frequencies and refine ACMG classification of reported BrS7 variants.
4. Genotype-stratified cohort analysis pooling SCN3B carriers across international BrS registries to estimate penetrance, event rates, and therapy response versus SCN5A and gene-negative patients.
5. Structural biology of the β3 Ig domain–Nav1.5 interface (cryo-EM / AlphaFold-Multimer) to map how V110I/T138del disrupt trafficking and gating.
6. Systematic drug-safety curation of I_Na-blocking agents and emerging triggers (e.g., tyrosine-kinase inhibitors) for carrier avoidance lists.

Report compiled from ~61 PubMed records. Key PMIDs: 23257389, 39761910, 19796257, 24657694, 41738055, 29959160, 21051419, 40996547, 40088219, 29761670, 42411811, 42200267, 41819241, 40130219, 38426305, 40245999, 36362949. Evidence source legend: human clinical (cohorts, case reports, consensus), in-vitro electrophysiology (HEK293 heterologous expression, canine wedge), model organism (Scn3b-KO mouse), computational/curation (ClinGen gene validity).

Artifacts

• OpenScientist final report
• OpenScientist final report

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• MONDO:0013481 (1 mention) - the report calls it "brugada syndrome 7"; MONDO calls it chromosome 13q14 deletion syndrome
• HP:0031650 (1 mention) - the report calls it "ECG sign"; HP calls it Abnormal atrioventricular valve physiology
• HP:0001279 (1 mention) - the report calls it "Symptom"; HP calls it Syncope
• HP:0001645 (1 mention) - the report calls it "Outcome"; HP calls it Sudden cardiac death
• HP:0005110 (1 mention) - the report calls it "Clinical sign"; HP calls it Atrial fibrillation
• HP:0012722 (1 mention) - the report calls it "ECG sign"; HP calls it Heart block
• NCIT:C50032 (1 mention) - the report calls it "Implantable Cardioverter-Defibrillator"; NCIT calls it Limiter Device
• NCIT:C371 (1 mention) - the report calls it "Isoproterenol"; NCIT calls it Chromomycin Antineoplastic Antibiotic
• NCIT:C99521 (1 mention) - the report calls it "Catheter Ablation"; NCIT calls it Percutaneous Coronary Intervention

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• GO:0086067 (1 mention) - the report calls it "bundle of His cell–Purkinje conduction"; GO calls it AV node cell to bundle of His cell communication
• UBERON:0000948 (1 mention) - the report calls it "Organ: heart"; UBERON calls it heart**, and lists "branchial heart" among its other names

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA.